No difference in treatment outcome between patients with nodal versus extranodal diffuse large B-cell lymphoma.

Saqib Raza Khan,Afzal Muhammad,Salman Muhammad Soomar,Daania Shoaib,Ayesha Arshad Ali,Tariq Muhammad,Muhammad Nauman Zahir,Adnan Abdul Jabbar,Yasmin Abdul Rashid,Michal Heger,Munira Shabbir Moosajee

Journal of clinical and translational research（2023）

引用 0|浏览26

暂无评分

摘要

DLBCL is an aggressive type of non-Hodgkin's lymphoma, however; patients respond well to standard systemic chemotherapy. Extranodal type of DLBCL patients tend to have more residual disease after first-line systemic chemotherapy, but physicians should keep in mind that the subsequent line treatment mitigates its negative impact on survival.

查看译文

关键词

Chemotherapy,Double hit lymphoma,Germinal center B cell-like,Immunotherapy,Lymphatic cancer,Survival,Treatment outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要